We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




NIV Test Developed for Fetal Rhesus Factor

By LabMedica International staff writers
Posted on 30 May 2018
If the blood of a pregnant woman is rhesus-negative (Rh-negative) and the blood of the fetus is rhesus-positive (Rh-positive), the woman may develop antibodies, which can cause severe harm to subsequent children in particular.

A test has now become available to determine the fetal Rhesus factor already before birth. More...
This is a non-invasive procedure, in which the fetus is not touched. Instead, the test analyses so-called cell-free fetal DNA circulating in the maternal plasma.

All Rh-negative pregnant women in Germany currently receive a standard dose of anti-D immunoglobulin. These antibodies are used to prevent sensitization by catching erythrocytes that reach the mother's bloodstream from the fetal bloodstream already before birth. Human anti-D immunoglobulin from sensitized donors is used for this prophylaxis. After birth, the infant's Rhesus factor is determined using a blood sample of the infant (postnatal testing). If the blood of the newborn is Rh-positive, the mother receives another anti-D prophylaxis.

The German Institute for Quality and Efficiency in Health Care (IQWiG, Cologne, Germany) has now examined whether the management of prophylaxis based on a new test has advantages or disadvantages for the children or for the expectant mothers. The final results are now available. According to the findings, there are no studies to answer this question. The reliability of the new test is as high as the reliability of the conventional test used after birth, however. In principle, this allows limiting prenatal anti-D prophylaxis only to those Rh-negative pregnant women whose fetus is Rh-positive according to the prenatal test. Currently, about 15 % of all pregnant women receive the prophylaxis, corresponding to about 110,000 pregnant women per year. Implementing the new test could reduce this number to about 60,000.

The team wanted to know whether the introduction of the new test can have health advantages or disadvantages for children or mothers, e.g. increasing the occurrence of hemolytic anemia or decreasing the occurrence of side effects of the prophylaxis. However, there are studies that provide information on how reliable the prenatal test is in determining the child's Rhesus factor. The reliability is comparatively high, which is referred to as "high diagnostic accuracy": The test correctly identifies 99.9% of all Rh-positive fetuses (sensitivity) and 99.1% of all Rh-negative fetuses (specificity). This means that 0.1% of pregnant women who would require anti-D prophylaxis before birth would not receive this prophylaxis if this decision was based on the test result. Hence, the prenatal test is as reliable as testing after birth.

The authors of the report stated that if the prenatal test was to replace the postnatal test, this would increase neither the rate of prophylaxis that is falsely withheld nor the rate of hemolytic anemia to a measurable extent. This is because both tests are equivalent. It is recommended, however, to evaluate the procedure first and particularly to test how high the sensitivity of the new prenatal test actually is under the health care conditions in Germany. The final report was issued on May 15, 2018.

Related Links:
German Institute for Quality and Efficiency in Health Care


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.